The fusion reaction was resumed when the temperature was raised to 37C

The fusion reaction was resumed when the temperature was raised to 37C. CD4i regions could be efficiently targeted by small molecule entry inhibitors. Human immunodeficiency virus type 1 (HIV-1) entry into host cells is initiated by the binding of the gp120 subunit of the viral envelope glycoprotein (Env) complex to the host cell receptor (CD4) (8,20). This interaction induces conformational changes in gp120 resulting in the exposure of a conserved high-affinity binding site for the coreceptor (the chemokine receptors CCR5 or CXCR4) (46,47,54,56,59). A Benzoylhypaconitine second obligatory binding step between the gp120-CD4 complex and the coreceptor is then thought to induce additional conformational changes that ultimately result in the fusion of viral and host cell membranes (9,18). Neutralizing antibodies are believed to act, at least in part, by binding to the exposed Env surface and obstructing the initial interaction between a trimeric array of gp120 molecules on the virion surface and receptor molecules on the target cell (36,37,57). In response, HIV-1 has evolved a number of strategies to evade recognition by neutralizing antibodies, particularly those directed to the conserved CD4 and coreceptor binding sites of Env. Benzoylhypaconitine The extent of protection of these sites from antibody recognition is limited by the necessity to preserve the accessibility for receptor interaction. In the case of the CD4bs this has led to the following structural features: (i) it is partially obscured from antibody recognition by the V1/V2 loop and associated carbohydrate structures; (ii) the flanking residues are variable and modified by glycosylation; (iii) it is recessed to an extent that limits direct access by an antibody Benzoylhypaconitine variable region; (iv) clusters of residues within the CD4bs that do not directly interact with CD4 are subject to variation among virus strains; (v) many gp120 residues interact with CD4 via LRIG2 antibody main-chain atoms, allowing for variability in the corresponding amino acid side chains (26); and (vi) there is considerable conformational flexibility within the CD4-unbound state of gp120, and antibody binding therefore requires relatively large entropic decreases, thus conformationally masking the conserved CD4bs (23,33). The Benzoylhypaconitine coreceptor binding site on gp120 is thought to be composed of a highly conserved element on the 19 strand and parts of the V3 loop (41,42,61). These elements are masked by the V1/V2 variable loops in the CD4-unbound state and largely unavailable for antibody binding (55,59). Upon CD4 binding, conformational changes are induced; these changes include displacement of the V1/V2 stem-loop structure and consequent exposure of the coreceptor binding site (31,47,60). Binding studies with variable loop-deleted mutants suggest that CD4 induces additional rearrangement or stabilization of the gp120 bridging sheet near the 19 strand to form the final coreceptor binding surface (59,61). Since the binding to CD4 occurs at the virus-cell interface, the exposed coreceptor binding site is optimally positioned for interaction with the coreceptor. A highly conserved discontinuous structure on gp120 associated with the coreceptor binding site is recognized by monoclonal antibodies (MAbs) that bind better to gp120 upon ligation Benzoylhypaconitine with CD4. These so-called CD4-induced (CD4i) antibodies, such as 17b and 48d (54,60), recognize a cluster of gp120 epitopes that are centered on the 19 strand and partially overlap the coreceptor binding site (41,42,55,59). Although such CD4i MAbs can neutralize some T-cell line-adapted HIV-1 strains, they are generally poorly neutralizing for primary isolates (40). However, we recently reported the isolation of an antibody Fab.